Article Versions Notes

Chiang H-C, Lee Y-C, Chang T-T, Lin Y-J, Wu H-T, Wang C-T, Chen C-Y, Chen P-J, Hsieh M-T, Lin S-H, et al. Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma. Cancers. 2023; 15(3):854. https://doi.org/10.3390/cancers15030854

Chiang, Hsueh-Chien, Yang-Cheng Lee, Ting-Tsung Chang, Yih-Jyh Lin, Hung-Tsung Wu, Chung-Teng Wang, Chiung-Yu Chen, Po-Jun Chen, Ming-Tsung Hsieh, Sheng-Hsiang Lin, and et al. 2023. "Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma" Cancers 15, no. 3: 854. https://doi.org/10.3390/cancers15030854

Chiang, H.-C., Lee, Y.-C., Chang, T.-T., Lin, Y.-J., Wu, H.-T., Wang, C.-T., Chen, C.-Y., Chen, P.-J., Hsieh, M.-T., Lin, S.-H., Chen, S.-H., Chuang, C.-H., Wu, I.-C., Hong, T.-C., Wu, J.-S., Han, M.-Z., Chen, W.-T., Chiang, C.-M., Hung, K.-K., & Kuo, H.-Y. (2023). Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma. Cancers, 15(3), 854. https://doi.org/10.3390/cancers15030854